NCT00220168已完成4 期
A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Response rates
研究概览
简要总结
The objective of this study is to assess the efficacy and toxicity of a 3 weekly regimen containing irinotecan combined with capecitabine in the setting of relapsed or refractory upper gastrointestinal tumours. Patients with locally advanced or metastatic adenocarcinoma or squamous cell carcinoma originating from the oesophagus, oesophagogastric junction or stomach who have previously received chemotherapy and have either failed to respond or who have relapsed within 3 months after an initial response will be eligible for treatment in this study.
The response rate, failure-free survival and overall survival of treated patients will be evaluated. Toxicity and quality of life will also be monitored closely.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven adenocarcinoma or squamous cell carcinoma of oesophagus, O-G junction and stomach, not amenable to surgical resection.
- •Bidimensionally measurable disease, or unidimensional measurable disease assessable by CT scanning, not within previously irradiated areas.
- •Patients with progressive disease during previous chemotherapy treatment or within three months of stopping treatment.
- •At least one previous chemotherapy regimen, given within 3 months prior to inclusion in this study.
- •No previous exposure to irinotecan.
- •Adequate bone marrow function with platelets >100 X 109/L; WBC > 3 X 109/L; Neutrophils > 1.5 X 109/L at the time of study entry.
- •Satisfactory renal function. Creatinine clearance (measured by Cockcroft and Gault) >50ml/min and Cr <
- •Satisfactory liver function:
- •In the absence of liver metastases: Bilirubin < 1.25N (N=upper limit of normal range) Hepatic transaminases < 2.5N Prothrombin time < 1.5N
- •In the presence of liver metastases: Bilirubin < 1.5N Hepatic transaminases < 5N Prothrombin time < 1.5N
- •No uncontrolled medical condition
- •No previous malignant disease except for non-melanotic skin cancer or in-situ carcinoma of the uterine cervix.
- •ECOG performance status of 0, 1 or
- •Predicted life expectancy of > 3 months.
- •Adequate contraceptive precautions
- •Informed written consent
排除标准
- •Medical or psychiatric conditions resulting in inability of patient to give written consent.
- •ECOG Performance status >2
- •Intracerebral metastases or meningeal carcinomatosis
- •Unresolved bowel obstruction
- •Creatinine clearance <50ml/min, Cr >135
- •Uncontrolled angina pectoris, heart failure (New York heart classification 3 or 4).
- •Pregnancy/lactation
- •Previous malignancy other than adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.
结局指标
主要结局
Response rates
Time to disease progression (TTP)
次要结局
- Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements).
- Survival
- Quality of life
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Inotersen in Familial Amyloid PolyneuropathyFamilial Amyloid PolyneuropathyTTRTransthyretinAmyloidosisFAPNCT01737398Ionis Pharmaceuticals, Inc.173
已完成
2 期
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungAdenocarcinomaNCT02875340ValiSeek Limited8
进行中（未招募）
1 期
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung CancerNon-small Cell Lung CancerNCT06114511Sichuan Baili Pharmaceutical Co., Ltd.78
已完成
2 期
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular DegenerationMacular DegenerationNCT00259753OPKO Health, Inc.120
已完成
2 期
Safety Evaluation of 3K3A-APC in Ischemic StrokeIschemic StrokeNCT02222714ZZ Biotech, LLC110